Zafgen appoints Dennis Kim CMO
This article was originally published in Scrip
Executive Summary
Zafgen, a pharmaceutical company developing novel obesity therapeutics, has named Dr Dennis Kim chief medical officer. Dr Kim is an endocrinologist with over 10 years' experience in the biotech and medical technology industries. He most recently served at Orexigen Therapeutics in multiple senior roles, including senior vice-president and head of obesity/metabolic diseases.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.